P1.13A.13 ALISertib in Patients with Extensive-Stage Small-Cell Lung Cancer: The Phase 2 ALISCA-Lung1 Study

Authors

T. Owonikoko
T. F. Burns
A. A. Chiappori
B. Drapkin
R. D. Gentzler
J. Goldschmidt
D. Hakimian
R. Jotte
S. V. Liu
A. A. Onitilo
N. A. Pennell
Bindu Potugari, Henry Ford HealthFollow
J. Rios
J. Sands
A. Spira
B. Wang
D. M. Waterhouse
B. Lowenthal
J. Bebchuk
L. D. Eli
E. K. Wong
A. Dowlati

Recommended Citation

Owonikoko T, Burns TF, Chiappori AA, Drapkin B, Gentzler RD, Goldschmidt J, Hakimian D, Jotte R, Liu SV, Onitilo AA, Pennell NA, Potugari B, Rios J, Sands J, Spira A, Wang B, Waterhouse DM, Lowenthal B, Bebchuk J, Eli LD, Wong EK, Dowlati A. P1.13A.13 ALISertib in Patients with Extensive-Stage Small-Cell Lung Cancer: The Phase 2 ALISCA-Lung1 Study. J Thorac Oncol 2024; 19(10):S212-S213.

Document Type

Conference Proceeding

Publication Date

10-1-2024

Publication Title

J Thorac Oncol

Volume

19

Issue

10

First Page

S212

Last Page

S213